TECHNOLOGY:
Rapid Saliva Detection for Covid-19 Virus
AFFILIATION:
Transversal Therapeutics, Haverhill, Massachusetts, United States
TECHNOLOGY SUMMARY
Area:
Diagnostic technologies for identification of SARS-CoV-2 from human nasal, buccal, or saliva samples
Tech Brief: Our aim is to commercialize a rapid 3-5 minute test for COVID-19 detection from collection of saliva to displaying of the result at a price of around $10 per test that can be used specifically for home, POC screening at hospitals, workplaces, and ports of entry. Non Invasive
SHOWCASE SUMMARY
Org Type:
Early-stage Startup (Seed)
FIGURES OF MERIT
Value Proposition: We are seeking a partner to support and commercialize this product financially by scaling up the production line in three months for clinical trials and 6 months to EUA authorization. For long term, it could work for other viruses if an antibody is available